1. Therapeutische domeinen
  2. Oncologie
  3. Borstkanker
  4. Borstkanker in een vroeg stadium
  5. Terugkerende borstkanker

Terugkerende borstkanker

Breast Cancer Recurrence

Risk of recurrence is routinely assessed by clinicians to understand prognosis and direct treatment decisions for each patient diagnosed with eBC.1,2 

References: 1, 2, 3 and 4

Micrometastases 

References: 2

Early recurrence vs. late recurrence. 2, 5, 6

References: 2, 4, and 6

Treatment recommendations depend on the risk of recurrence. 7-10

References: 7, 8, 9, and 10

The intent of eBC treatment is curative, but the risk of recurrence remains a significant problem. 11

References: 11,12, and 13

 

CT, chemotherapy; eBC, early breast cancer; ET, endocrine therapy; gBRCA, germline breast cancer gene; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mBC, metastatic breast cancer; RT, radiation therapy

  1. Canadian Cancer Society. Risk of recurrence after surgery and additional treatments. Assessed on April 14, 2023. Available at: https://cancer.ca/en/cancer-information/cancer-types/breast/treatment/risk-of-breast-cancer-recurrence-and-adjuvant-therapy.
  2. Wangchinda P, Ithimakin S. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J Surg Oncol. 2016;14(1):223.
  3. Friberg S, Nyström A. Cancer Metastases: Early Dissemination and Late Recurrences. Cancer Growth Metastasis. 2015;8:43-49.
  4. Chew HK. Adjuvant therapy for breast cancer: who should get what. West J Med. 2001;174(4):284-287.
  5. Gomis RR, Gawrzak S. Tumor cell dormancy. Mol Oncol. 2017;11(1):62-78.
  6. American Cancer Society (ACS). Treating Breast Cancer. Atlanta, GA: January 2023:1-115.
  7. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(8):1194-1220.
  8. European Medicines Agency. Verzenios Summary of opinion1 (post authorisation). February 24 2022.
  9. AstraZeneca. Press release. August 4, 2022.
  10. Gradishar WJ, Moran MS, Abraham J et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast Cancer. V.4.2023. National Comprehensive Cancer Network® (NCCN®). March 2023:1-256.
  11. Scharl A, Kühn T, Papathemelis T, et al. The Right Treatment for the Right Patient - Personalised Treatment of Breast Cancer. Geburtshilfe Frauenheilkd. 2015;75(7):683-691.
  12. Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 Years. N Engl J Med. 2017;377(19):1836-1846.
  13. Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 Years. N Engl J Med. 2017;377(19)(suppl):1-40.
BE2308303564
Oncologie
Afdrukken
×

Ask the speakers